OR WAIT null SECS
April 07, 2023
FDA aims to address mounting criticisms of its accelerated approval pathway.
Lonza and ABL Bio are collaborating on the development and manufacture of bispecific antibody product.
NextPharma has acquired a leading European chewable tablets manufacturing site from Takeda in Asker, Norway.
April 05, 2023
Sartorius’ acquisition of Polyplus is designed to strengthen its cell and gene therapy capabilities.
April 04, 2023
A CPHI North America panel discussion forewarns that CDMO supply chains are potentially the biggest single risk to product resilience.
April 02, 2023
A further setback to the publication of the pharmaceutical legislative changes in Europe may mean time is running out for appropriate review before 2024 parliamentary elections.
March 31, 2023
FDA has approved Evkeeza for young children with homozygous familial hypercholesterolemia.
March 30, 2023
Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.
CDMO Exothera and biotech company Remedium are joining forces to scale up the manufacturing process for Remedium’s lead gene therapy candidate for treating osteoarthritis.
Takeda plans to build a new facility in Osaka, Japan, for the manufacture of plasma-derived therapies.